---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-26-000071"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2026-10-14T11:57:03+00:00"
generated_at: "2026-10-14T12:00:06.339363+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Akebia Chief Commercial Officer Nicholas Grund resigns effective Nov 6; stays on as consultant

## Summary
- Nicholas Grund, SVP and Chief Commercial Officer, notified Akebia on Oct 7, 2026 of his resignation for personal reasons; effective Nov 6, 2026.
- Grund and the company entered into a Consulting Agreement on Oct 13, 2026, effective as of the Nov 6 resignation date.
- Consulting period runs until April 30, 2027, terminable by the company on 10 days' notice or by Grund on 30 days' notice.
- Grund will be paid an hourly rate for consulting services during the period; no successor was named in the filing.
- Filing signed by President and CEO John P. Butler on October 14, 2026.

## SEC filing metadata
- accession: 0001517022-26-000071
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2026-10-14T11:57:03+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000071/0001517022-26-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000071/akba-20261007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-26-000071
- JSON: https://secwatch.observer/filing/0001517022-26-000071.json
- Plain text: https://secwatch.observer/filing/0001517022-26-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.